Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺/NADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside [NR]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 600 mg | Experimental |
| |
| 300 mg | Experimental |
| |
| 0 mg | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotinamide Riboside (NR) | Dietary Supplement | 600 mg NR |
| |
| Nicotinamide Riboside (NR) |
| Measure | Description | Time Frame |
|---|---|---|
| Substrate utilization (CHO and fat oxidation rate) | From enrollment to the end of treatment at 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Oxygen consumption | From enrollment to the end of treatment at 4 weeks | |
| Heart rate | From enrollment to the end of treatment at 4 weeks | |
| Blood glucose concentration |
| Measure | Description | Time Frame |
|---|---|---|
| Height | From enrollment to the end of treatment at 4 weeks | |
| Weight | From enrollment to the end of treatment at 4 weeks | |
| Power output at VT1 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| G02, Kwok Sports Building, The Chinese University of Hong Kong | Recruiting | Hong Kong | Please Select | 999077 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C018613 | nicotinamide-beta-riboside |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Dietary Supplement |
300 mg NR |
|
| From enrollment to the end of treatment at 4 weeks |
| Blood lactate concentration | From enrollment to the end of treatment at 4 weeks |
| Peak power output | From enrollment to the end of treatment at 4 weeks |
| Mean power output | From enrollment to the end of treatment at 4 weeks |
| Rating of perceived exertion | From enrollment to the end of treatment at 4 weeks |
| Muscle pain scale | Muscle pain scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle pain. | From enrollment to the end of treatment at 4 weeks |
| Muscle fatigue scale | Muscle fatigue scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle fatigue. | From enrollment to the end of treatment at 4 weeks |
| From enrollment to the end of treatment at 4 weeks |
| Health history questionnaire | This questionnaire includes questions regarding participant's present/past history of diseases and his/her family history of diseases. | From enrollment to the end of treatment at 4 weeks |
| International Physical Activity Questionnaire (IPAQ) | IPAQ is a validated questionnaire to measure the physical activity of participants during the past 7 days. The score will be transformed to metabolic equivalents of tasks per week (METs/week), with higher value indicating greater participation in physical activity. | From enrollment to the end of treatment at 4 weeks |